| McAllister, Peter |
NCT03337620: Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine |
|
|
| Completed | 3 | 174 | US | Tx360 | Tian Medical Inc., TAMM Net, Inc., Clinvest Research, LLC, Ki Health Partners. LLC | Headache, Migraine | 11/23 | 12/23 | | |
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
|
|
| Completed | 3 | 523 | Europe, US | buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo | Annovis Bio Inc., TFS Trial Form Support | Parkinson's Disease, Idiopathic | 12/23 | 12/23 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 375 | Europe, US, RoW | Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo | Suven Life Sciences Limited, Suven Life Sciences Ltd | Agitation, Alzheimer's Type Dementia | 01/25 | 01/25 | | |
| Active, not recruiting | 3 | 1083 | Canada, US, RoW | Simufilam, PTI-125, Placebo | Cassava Sciences, Inc., Premier Research Group plc | Alzheimer Disease | 05/25 | 05/25 | | |
| Active, not recruiting | 3 | 1667 | Japan, US | Remternetug (IV), LY3372993, Remternetug (SC), Placebo | Eli Lilly and Company | Alzheimer's Disease | 06/24 | 03/26 | | |
| Recruiting | 3 | 800 | Europe, Canada, Japan, US, RoW | Remibrutinib, LOU064, Teriflunomide | Novartis Pharmaceuticals, Novartis Pharma AG | Relapsing Multiple Sclerosis | 04/26 | 10/30 | | |
| Recruiting | 3 | 1633 | Europe, Japan, US, RoW | Lasmiditan, LY573144, Placebo | Eli Lilly and Company | Migraine | 01/25 | 01/25 | | |
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Lasmiditan, LY573144 | Eli Lilly and Company | Migraine | 03/26 | 03/26 | | |
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD |
|
|
| Completed | 2/3 | 320 | US | Buntanetap/Posiphen, Posiphen Tartrate, Placebo | Annovis Bio Inc. | Alzheimer Disease | 02/24 | 02/24 | | |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
| Completed | 2 | 153 | Europe, US, RoW | CT1812, Study Drug, Placebo, Matching Placebo | Cognition Therapeutics, National Institute on Aging (NIA) | Mild to Moderate Alzheimer's Disease | 05/24 | 05/24 | | |
| Townley, Ryan |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
| Completed | 1/2 | 50 | US | Pepinemab, Placebo | Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association | Alzheimer Disease | 06/24 | 06/24 | | |
| Completed | N/A | 220 | US | | University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health | Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia | 04/24 | 04/24 | | |
| Montero, Alexandria |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
BIO-HERMES-001, NCT04733989: A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes) |
|
|
| Completed | N/A | 1002 | US | Biomarker Data Collection | GAP Innovations, PBC | Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment | 11/22 | 11/22 | | |
| Tolea, Magdalena |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
| Completed | N/A | 336 | US | Provider Educational Intervention | Florida Atlantic University, University of Miami, Palm Beach State College | Alzheimer' Disease | 09/23 | 09/23 | | |
NCT05479552: A Diagnostic Test for Dementia With Lewy Bodies |
|
|
| Active, not recruiting | N/A | 80 | US | Syn-One Test | CND Life Sciences, National Institute on Aging (NIA) | MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies | 09/25 | 10/25 | | |
| Pao, Linda |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies |
|
|
| Active, not recruiting | 2 | 130 | US | CT1812 | Cognition Therapeutics, National Institute on Aging (NIA) | Dementia With Lewy Bodies | 11/24 | 11/24 | | |
| Active, not recruiting | 2 | 160 | Europe, US | Neflamapimod, VX-745, Placebo | EIP Pharma Inc, National Institute on Aging (NIA), Worldwide Clinical Trials, CervoMed, Inc | Dementia With Lewy Bodies | 08/24 | 03/25 | | |
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease |
|
|
| Recruiting | 2 | 300 | Japan, US | Mevidalen, LY3154207, Placebo | Eli Lilly and Company | Alzheimer Disease | 12/25 | 01/26 | | |
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 540 | US | CT1812, Study Drug Active, Placebo, Matching Placebo | Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium | Early Alzheimer's Disease | 04/27 | 04/27 | | |
NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD) |
|
|
| Recruiting | 1 | 128 | US | PMN310, Placebo | ProMis Neurosciences, Inc | Alzheimer Disease, Early Onset | 07/26 | 12/26 | | |
Bio-Hermes-002, NCT06584357: Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia |
|
|
| Recruiting | N/A | 1200 | US | Biomarker Data Collection, MK6240 | GAP Innovations, PBC | Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment | 07/28 | 07/28 | | |
